These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15617300)

  • 21. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects.
    Bemelmans BL; Kiemeney LA; Debruyne FM
    Eur Urol; 2000 Jun; 37(6):709-13. PubMed ID: 10828672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of oxybutynin treatment on cognition in children with diurnal incontinence.
    Sommer BR; O'Hara R; Askari N; Kraemer HC; Kennedy WA
    J Urol; 2005 Jun; 173(6):2125-7. PubMed ID: 15879864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal oxybutynin. A viewpoint by Adrian Wagg.
    Wagg A
    Drugs Aging; 2003; 20(11):865-6. PubMed ID: 12964894
    [No Abstract]   [Full Text] [Related]  

  • 24. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth.
    Corcos J; Casey R; Patrick A; Andreou C; Miceli PC; Reiz JL; Harsanyi Z; Darke AC;
    BJU Int; 2006 Mar; 97(3):520-7. PubMed ID: 16469019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. POEMS (patient-oriented evidence that matters) spark discussion.
    Weiss BD
    J Fam Pract; 2001 Oct; 50(10):901. PubMed ID: 11674898
    [No Abstract]   [Full Text] [Related]  

  • 26. Urinary incontinence, hyperthermia, and sudden death.
    Herbst J; Gilbert JD; Byard RW
    J Forensic Sci; 2011 Jul; 56(4):1062-3. PubMed ID: 21470226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticholinergic drugs for overactive bladder.
    Kripke C
    Am Fam Physician; 2006 Jan; 73(1):66. PubMed ID: 16417066
    [No Abstract]   [Full Text] [Related]  

  • 29. [Use of driptan (oxybutinin) in patients with urgent forms of urination disorders].
    Loran OB; Pushkar' DIu; Tevlin KP
    Urol Nefrol (Mosk); 1998; (6):24-6. PubMed ID: 10051823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of Medicare drug formulary drugs for treatment of overactive bladder.
    Grocela JA; Kanji A; Ternullo J
    J Urol; 2006 Jul; 176(1):252-5; discussion 255-6. PubMed ID: 16753413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
    Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV
    Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
    Perfetto EM; Subedi P; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute-angle closure glaucoma as a side-effect of oxybutynin.
    Sung VC; Corridan PG
    Br J Urol; 1998 Apr; 81(4):634-5. PubMed ID: 9598644
    [No Abstract]   [Full Text] [Related]  

  • 34. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group.
    Anderson RU; Mobley D; Blank B; Saltzstein D; Susset J; Brown JS
    J Urol; 1999 Jun; 161(6):1809-12. PubMed ID: 10332441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gelnique (oxybutynin chloride) 10% gel for overactive bladder.
    Lajiness MJ
    Urol Nurs; 2010; 30(4):253-4. PubMed ID: 20949812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Intravesical oxybutynin hydrochloride in the treatment of urge incontinence in the elderly].
    Mizunaga M; Miyata M; Kaneko S; Taniguchi N; Yachiku S; Chiba K; Osanai H; Fujisawa M
    Nihon Hinyokika Gakkai Zasshi; 1996 Jun; 87(6):923-7. PubMed ID: 8753011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low dose oxybutynin for the unstable bladder.
    Malone-Lee J; Lubel D; Szonyi G
    BMJ; 1992 Apr; 304(6833):1053. PubMed ID: 1586797
    [No Abstract]   [Full Text] [Related]  

  • 38. Exaggerated neurological side-effects of oral and intravesical oxybutynin in a patient with multiple sclerosis.
    Vaidyanathan S; Krishnan KR; Soni BM; Fraser MH
    Spinal Cord; 1997 Mar; 35(3):190-1. PubMed ID: 9076875
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.
    Gleason DM; Susset J; White C; Munoz DR; Sand PK
    Urology; 1999 Sep; 54(3):420-3. PubMed ID: 10475346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.